PL3789389T3 - Postać krystaliczna (s)-n-[5-[1-(3-etoksy-4-metoksyfenylo)-2-(metylosulfonylo)etylo]-4,6-diokso-5,6-dihydro-4h-tieno[3,4-c]pirol-1-ilo]acetamidu - Google Patents

Postać krystaliczna (s)-n-[5-[1-(3-etoksy-4-metoksyfenylo)-2-(metylosulfonylo)etylo]-4,6-diokso-5,6-dihydro-4h-tieno[3,4-c]pirol-1-ilo]acetamidu

Info

Publication number
PL3789389T3
PL3789389T3 PL19797143.5T PL19797143T PL3789389T3 PL 3789389 T3 PL3789389 T3 PL 3789389T3 PL 19797143 T PL19797143 T PL 19797143T PL 3789389 T3 PL3789389 T3 PL 3789389T3
Authority
PL
Poland
Prior art keywords
pyrol
thieno
dioxo
methylsulfonyl
acetamide
Prior art date
Application number
PL19797143.5T
Other languages
English (en)
Polish (pl)
Inventor
Donglei ZHANG
Liyu WANG
Yukun CHANG
Original Assignee
Tianjin Hemay Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Hemay Pharmaceutical Co., Ltd. filed Critical Tianjin Hemay Pharmaceutical Co., Ltd.
Publication of PL3789389T3 publication Critical patent/PL3789389T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
PL19797143.5T 2018-05-02 2019-04-30 Postać krystaliczna (s)-n-[5-[1-(3-etoksy-4-metoksyfenylo)-2-(metylosulfonylo)etylo]-4,6-diokso-5,6-dihydro-4h-tieno[3,4-c]pirol-1-ilo]acetamidu PL3789389T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810407741 2018-05-02
PCT/CN2019/085327 WO2019210864A1 (zh) 2018-05-02 2019-04-30 噻吩衍生物的晶型

Publications (1)

Publication Number Publication Date
PL3789389T3 true PL3789389T3 (pl) 2026-03-16

Family

ID=68386284

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19797143.5T PL3789389T3 (pl) 2018-05-02 2019-04-30 Postać krystaliczna (s)-n-[5-[1-(3-etoksy-4-metoksyfenylo)-2-(metylosulfonylo)etylo]-4,6-diokso-5,6-dihydro-4h-tieno[3,4-c]pirol-1-ilo]acetamidu

Country Status (14)

Country Link
US (4) US11396518B2 (enExample)
EP (5) EP3800190A4 (enExample)
JP (5) JP7477459B2 (enExample)
KR (4) KR102686835B1 (enExample)
CN (7) CN116836178A (enExample)
AU (4) AU2019262284A1 (enExample)
BR (4) BR112020022190A2 (enExample)
CA (4) CA3099072A1 (enExample)
DK (1) DK3789389T3 (enExample)
ES (1) ES3047059T3 (enExample)
FI (1) FI3789389T3 (enExample)
PL (1) PL3789389T3 (enExample)
PT (1) PT3789389T (enExample)
WO (4) WO2019210865A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3800190A4 (en) * 2018-05-02 2022-01-26 Tianjin Hemay Pharmaceutical Co., Ltd. SOLID FORM OF THIOPHENE DERIVATIVE
WO2025103428A1 (zh) * 2023-11-14 2025-05-22 赣州和美药业股份有限公司 中重度斑块型银屑病的治疗

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
WO2003091260A1 (en) * 2002-04-23 2003-11-06 Dr. Reddy's Laboratories Limited Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof
CN101186612B (zh) 2006-11-15 2012-10-03 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用
CN108059635B (zh) * 2009-05-14 2021-10-01 天津合美医药科技有限公司 噻吩衍生物
JP5968881B2 (ja) * 2010-06-30 2016-08-10 レオ ファーマ アクティーゼルスカブ カルシウム模倣化合物の新規多形
WO2015082583A1 (en) * 2013-12-05 2015-06-11 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
UA116182C2 (uk) 2014-07-18 2018-02-12 Ґрін Кросс Корпорейшн Кристалічна форма метансульфонату 5-хлор-n-({(5s)-2-оксо-3-[4-(5,6-дигідро-4h-[1,2,4]триазин-1-іл)феніл]-1,3-оксазолідин-5-іл}метил)тіофен-2-карбоксаміду та фармацевтична композиція, що його містить
EP3144393A1 (en) * 2015-09-18 2017-03-22 LEK Pharmaceuticals d.d. A synthetic pathway towards apremilast
CN107417626B (zh) * 2016-05-23 2020-01-24 江苏奥赛康药业有限公司 一种2-氨基嘧啶类化合物的多晶型形式
CN107474057B (zh) * 2016-06-07 2021-03-12 天津药物研究院有限公司 (5-(2-腈基苄基)-4,5,6,7-四氢噻吩并[3,2-c]吡啶-2-基)乙酸酯盐酸盐的晶型及其制备方法和用途
US10570147B2 (en) * 2017-06-13 2020-02-25 Biotheryx, Inc. Bicyclic compounds and methods of use
JP7074782B2 (ja) * 2017-06-30 2022-05-24 トロフィー エスアーエス 患者位置決めアクセサリ検出を伴う口腔外歯科用撮像装置
EP3800190A4 (en) * 2018-05-02 2022-01-26 Tianjin Hemay Pharmaceutical Co., Ltd. SOLID FORM OF THIOPHENE DERIVATIVE

Also Published As

Publication number Publication date
BR112020021945A2 (pt) 2021-01-26
CA3098931C (en) 2023-10-24
AU2019262284A1 (en) 2020-12-24
JP2021522348A (ja) 2021-08-30
WO2019210867A1 (zh) 2019-11-07
CN116813637A (zh) 2023-09-29
FI3789389T3 (fi) 2025-11-19
CA3099072A1 (en) 2019-11-07
AU2019262282B2 (en) 2022-04-28
JP2021523891A (ja) 2021-09-09
CN116947878A (zh) 2023-10-27
CN110437251B (zh) 2023-07-21
AU2019262282A1 (en) 2020-11-12
US20210139498A1 (en) 2021-05-13
US11274104B2 (en) 2022-03-15
KR20210022557A (ko) 2021-03-03
PT3789389T (pt) 2025-12-17
CN110437249B (zh) 2023-07-21
DK3789389T3 (da) 2025-11-10
BR112020021976A2 (pt) 2021-01-26
CA3098927A1 (en) 2019-11-07
EP4335515A2 (en) 2024-03-13
ES3047059T3 (en) 2025-12-03
KR20210025001A (ko) 2021-03-08
WO2019210865A1 (zh) 2019-11-07
EP3789389B1 (en) 2025-10-08
EP4335515A3 (en) 2024-07-03
US12227514B2 (en) 2025-02-18
EP3789387B1 (en) 2024-02-28
EP3789389A1 (en) 2021-03-10
EP3789388B1 (en) 2024-01-24
CA3098931A1 (en) 2019-11-07
US20210238191A1 (en) 2021-08-05
AU2019262286A1 (en) 2020-11-12
CN110437251A (zh) 2019-11-12
EP3789389A4 (en) 2022-01-26
EP3800190A1 (en) 2021-04-07
CA3099071A1 (en) 2019-11-07
KR102701245B1 (ko) 2024-08-30
WO2019210864A1 (zh) 2019-11-07
BR112020022186A2 (pt) 2021-02-02
KR20210025000A (ko) 2021-03-08
CA3098927C (en) 2023-10-03
AU2019263865B2 (en) 2022-01-27
CA3213055A1 (en) 2019-11-07
JP7481263B2 (ja) 2024-05-10
JP7542523B2 (ja) 2024-08-30
CN110437250A (zh) 2019-11-12
CN110437249A (zh) 2019-11-12
US12180222B2 (en) 2024-12-31
JP2021523890A (ja) 2021-09-09
EP3789388A4 (en) 2021-06-09
KR20210022556A (ko) 2021-03-03
KR102839924B1 (ko) 2025-07-29
AU2019262286B2 (en) 2022-08-11
US11396518B2 (en) 2022-07-26
CN116836178A (zh) 2023-10-03
CN116854705A (zh) 2023-10-10
EP3800190A4 (en) 2022-01-26
JP2021523935A (ja) 2021-09-09
EP3789388A1 (en) 2021-03-10
KR102686835B1 (ko) 2024-07-22
CN110437250B (zh) 2023-06-23
EP3789387A1 (en) 2021-03-10
JP2024026251A (ja) 2024-02-28
US20210230181A1 (en) 2021-07-29
EP3789387A4 (en) 2021-06-30
WO2019210869A1 (zh) 2019-11-07
JP7477459B2 (ja) 2024-05-01
AU2019263865A1 (en) 2020-12-24
US20210380600A1 (en) 2021-12-09
BR112020022190A2 (pt) 2021-02-02

Similar Documents

Publication Publication Date Title
IL285783A (en) Jak inhibitor compound and use thereof
EP3903206A4 (en) HASHING-BASED EFFECTIVE USER MODELING
IL282468A (en) 2- amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
EP3767709A4 (en) POSITIVE ELECTRODE COMPOSITION FOR LITHIUM ION SECONDARY CELL, POSITIVE ELECTRODE FOR LITHIUM ION SECONDARY CELL, and LITHIUM ION SECONDARY CELL
EP3769479A4 (en) HIERARCHICAL BIT-INDEXED REPLICATION OF MULTICAST PACKAGES
EP3860449A4 (en) ELECTRODE ARRANGEMENT
EP3769477A4 (en) HIERARCHICAL BIT-INDEXED REPLICATION OF MULTICAST PACKAGES
EP3799602A4 (en) COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION
MA46791A (fr) Composés et procédés pour réduire l'expression d'atxn3
IL282375A (en) 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating α-synucleinopathies, tauopathies, and other disorders
EP3919491A4 (en) ACT INHIBITOR
CY1126466T1 (el) Παραγωγα φαινυλιου/πυριδυλ-νη-φαινυλιου/ πυριδυλιου για τη θεραπευτικη αντιμετωπιση ιικωνλοιμωξεων
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
EP3814911A4 (en) Controlling nand operation latency
DK3986920T3 (da) Tnfr2-agonister med forbedret stabilitet
PL3789389T3 (pl) Postać krystaliczna (s)-n-[5-[1-(3-etoksy-4-metoksyfenylo)-2-(metylosulfonylo)etylo]-4,6-diokso-5,6-dihydro-4h-tieno[3,4-c]pirol-1-ilo]acetamidu
EP3923983A4 (en) CHIMERIC RSV AND HMPV F PROTEINS, IMMUNOGENIC COMPOSITIONS AND METHODS OF USE
EP3819299A4 (en) HYPOXANTHINE COMPOUND
EP3935037A4 (en) USE OF 8,9-DIHYDROCANNABIDIOL COMPOUNDS
HUE059604T2 (hu) Eljárás 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindion és sói elõállítására
CO2017002266A2 (es) Derivados de 5-[3-metil-2-[(4-metillsulfonilpiperazin-1-il)metil]-7-morfolinotieno [2,3-c] piridinil como inhibidores de la quinasa pi3
EP4073640A4 (en) Low latency dynamic content management
JP2020506196A5 (ja) テビペネムピボキシル結晶形、それを含む組成物、製造方法、および使用方法
EP3500562A4 (en) SUBSTITUTED AZOLE DERIVATIVES FOR THE GENERATION, PROLIFERATION AND DIFFERENTIATION OF HEMATOPOIETIC STEM AND PRELIMINARY CELLS
EP3740468A4 (en) SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHOD OF USING